Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) CFO Raphi Levy sold 20,000 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $11.00, for a total value of $220,000.00. Following the completion of the transaction, the chief financial officer directly owned 110,180 shares in the company, valued at $1,211,980. This trade represents a 15.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Raphi Levy also recently made the following trade(s):
- On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total value of $167,125.00.
- On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00.
Alpha Tau Medical Price Performance
Shares of NASDAQ:DRTS opened at $10.88 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79. Alpha Tau Medical Ltd. has a 1-year low of $2.87 and a 1-year high of $11.62. The company has a market capitalization of $982.79 million, a P/E ratio of -16.24 and a beta of 1.19. The firm’s 50 day simple moving average is $9.39 and its two-hundred day simple moving average is $7.61.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Alpha Tau Medical in a research report on Tuesday, June 2nd. LADENBURG THALM/SH SH increased their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Piper Sandler boosted their price target on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday, May 19th. Finally, Citigroup upped their price target on Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $12.60.
Check Out Our Latest Research Report on Alpha Tau Medical
Hedge Funds Weigh In On Alpha Tau Medical
Several institutional investors have recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. purchased a new stake in shares of Alpha Tau Medical during the 3rd quarter worth approximately $62,000. Bank of America Corp DE boosted its position in shares of Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after acquiring an additional 21,677 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Alpha Tau Medical in the third quarter valued at $170,000. Mariner LLC grew its holdings in shares of Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after purchasing an additional 80,129 shares in the last quarter. Finally, Apella Capital LLC purchased a new stake in Alpha Tau Medical during the fourth quarter valued at $1,892,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.
About Alpha Tau Medical
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.
See Also
- Five stocks we like better than Alpha Tau Medical
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
